Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study.

Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol. 1990 Feb; 36(2):166-71.

View in: PubMed

subject areas

Combined Modality Therapy
Doxorubicin
Female
Humans
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasms, Unknown Primary
Random Allocation
Risk Factors
Survival Analysis
Uterine Neoplasms

authors with profiles

William Thomas Creasman